| Revenue growth | 36% YoY growth in Q4 FY26. |
|---|---|
| Margins | Q4 margins at 34.3%; long-term sustainable range guided at 26-28%. |
| Order book | CRAMS projects in Europe and Japan moving to commercial trial stage. |
| Demand visibility | Slow recovery in Europe; customers placing smaller, frequent orders. |
| Management confidence | High confidence in long-term structural strength despite challenging macro environment. |
Growth
Q4 FY26 revenue grew 36% YoY and 57% QoQ; EBITDA grew 15% YoY; PAT declined 5% YoY to INR 6.27 cr.
Outlook
Block-7 commercial production starts Q2 FY27; CRAMS projects transitioning to commercial trials; sustainable EBITDA margins targeted at 26-28%.
Risks
Geopolitical volatility, fluctuating raw material prices, and regulatory approval delays in Europe and Japan.
Earnings Call filed with BSE, NSE: SGRL. Summary written with AI assistance from the document.
Shree Ganesh Remedies Ltd: key numbers
- Share price
- ₹672.35
- Market cap
- ₹863.1 Cr
- Revenue (annual)
- ₹109.3 Cr
- Net profit (annual)
- ₹17.76 Cr
- P/E (TTM)
- 55.9×Sector 50.4×
- Promoter holding
- 72.84%+0.00% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Shree Ganesh Remedies Ltd
All →Shree Ganesh Remedies Annual General Meeting
Shree Ganesh Remedies held its 31st Annual General Meeting on September 12, 2026. The meeting transacted ordinary and special business items, including director and auditor appointments.
Shree Ganesh Remedies Investor Presentation: Key Takeaways
Q1FY27 was challenging with Revenue/PAT declining 42%/68% YoY due to subdued European demand and termination of a distributor agreement. Management shifted focus to direct customer engagement and CRAMS projects.
Shree Ganesh Remedies Q1 FY27 Results: Net Profit ₹1.1 Cr, Down 67.6% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹14.4 Cr (-41.7% YoY) and net profit of ₹1.1 Cr (-67.6% YoY) for Q1 FY27.
- Key figure
- Net profit ₹1.1 Cr · -67.6% YoY
Shree Ganesh Remedies Earnings Call: Key Takeaways
Management characterized FY26 as a consolidation year, focusing on groundwork for CRAMS. While Q4 showed strong sequential recovery, full-year growth remained flat as the company pivoted from generic domestic markets to specialized global molecules.
Shree Ganesh Remedies Earnings Call: Key Takeaways
Shree Ganesh Remedies reported stagnant FY26 revenue of ₹109.3cr with a 23% PAT decline to ₹17.8cr. Focus remains on scaling CRAMS and specialty chemicals via expansion.
Shree Ganesh Remedies Q4 FY26 Results: Net Profit ₹6.3 Cr, Down 4.5% YoY
Shree Ganesh Remedies Ltd reported revenue from operations of ₹33.2 Cr (+36.1% YoY) and net profit of ₹6.3 Cr (-4.5% YoY) for Q4 FY26.
- Key figure
- Net profit ₹6.3 Cr · -4.5% YoY